Evidence map›Paper›PMID 33225227›Full record

ReviewCardiovascular endocrinology & metabolism2020

Peroxisome proliferator-activated receptor agonists and reversal of vascular degeneration through DNA repair, a step toward drug-induced regenerative medicine.

Peter Afdal, Habiba-Allah Ismail, Mirette Ashraf, Nada Hafez, Nardine Nasry, Nouran Hafez, Nourhan Youssef, Nourhan Samy, Rana Saeed, Antoine Fakhry AbdelMassih

Open access · diamondAbstract readReview
In one paragraph

Review in Cardiovascular endocrinology & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Peter AfdalStudents and Internship Research Program (Research Accessibility Team).
Habiba-Allah IsmailStudents and Internship Research Program (Research Accessibility Team).
Mirette AshrafStudents and Internship Research Program (Research Accessibility Team).
Nada HafezStudents and Internship Research Program (Research Accessibility Team).
Nardine NasryStudents and Internship Research Program (Research Accessibility Team).
Nouran HafezStudents and Internship Research Program (Research Accessibility Team).
Nourhan YoussefStudents and Internship Research Program (Research Accessibility Team).
Nourhan SamyStudents and Internship Research Program (Research Accessibility Team).
Rana SaeedStudents and Internship Research Program (Research Accessibility Team).
Antoine Fakhry AbdelMassihPediatric Cardiology Unit, Pediatrics' Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Access to Wholistic and Productive Living Institute · USCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial dysfunction with subsequent degeneration and vasoocclusive remodeling is the hallmark of many cardiovascular disorders including pulmonary vascular disease (PVD). To date, the available treatments slows disease progression but does not prevent deterioration. Reversing such pathologies would spare many patients risky surgeries and long waiting lists for a possible organ donor. Peroxisome proliferator-activated receptor agonists were first introduced as sole insulin sensitizers, however, there is increasing body of evidence that they have different actions on DNA which might help reverse vascular degeneration. This effect appears to be mainly achieved through enhancement of DNA damage responses (DDR). The aforementioned effect could offer new insights about repurposing drugs for achieving organ or tissue regeneration, an understudied field named drug-induced regenerative medicine.

Identifiers

PMID33225227
PMCPMC7673771
OpenAlexW3036513404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.